What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials.

  • Josef S Smolen
  • Published 2007 in The Journal of rheumatology. Supplement
The recently approved therapies abatacept and rituximab have significantly improved treatment options for patients with rheumatoid arthritis, especially for patients who have an inadequate response to tumor necrosis factor inhibitors. This article reviews the latest efficacy and safety data for both abatacept and rituximab. One-year data from abatacept and… CONTINUE READING